Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2021-03-25 Director's Dealing
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
Director's Dealing 2021
Director's Dealing
2021-03-25 English
Director's Dealing 2021
Director's Dealing
2021-03-25 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 22, 2021, by Anixa Biosciences, Inc. The content describes the entry into a material definitive agreement related to an amended and restated underwriting agreement for a public offering of common stock. It details the terms of the offering, underwriting discounts, fees, and warrants issued to underwriters. The document includes exhibits such as the underwriting agreement and legal opinions. This type of filing is a current report disclosing significant events, specifically related to capital raising activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (6958 characters) and detailed content confirm it is not merely an announcement but a substantive filing about financing activity.
2021-03-24 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a Form 424B5 prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act. It details an offering of common stock and underwriter warrants, including pricing, underwriting discounts, use of proceeds, risk factors, and other offering-related information. It is a registration and offering document related to capital raising activities, not a financial report, earnings release, or management discussion. The presence of underwriting details, offering price, and registration statement references clearly indicate this is a capital/financing update filing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual offering document, not just an announcement or a brief notice.
2021-03-24 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 95% confidence The document is titled 'Free Writing Prospectus' and is filed pursuant to Rule 433 of the Securities Act of 1933. It discusses an offering of common stock by Anixa Biosciences, including details about the offering size, pricing, underwriter, and intended use of proceeds. It references a registration statement on Form S-3 and a preliminary prospectus supplement. The content is focused on a capital raising event and related disclosures, typical of a capital/financing update. There are no financial statements or comprehensive financial performance data, so it is not an Annual Report or Interim Report. It is not a regulatory filing of miscellaneous nature, but a specific financing announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (6965 characters) supports it being a substantive announcement rather than a brief report publication announcement.
2021-03-22 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 95% confidence The document is titled 'Free Writing Prospectus' and is filed pursuant to Rule 433 of the Securities Act of 1933. It announces a $10 million bought deal offering of common stock by Anixa Biosciences, including details about the underwriting agreement, share price, and intended use of proceeds. The document is a communication related to a securities offering, specifically a prospectus supplement and underwriting announcement. It does not contain financial statements, management discussion, or detailed financial results. It is not an annual or quarterly report, earnings release, or management report. Instead, it is an update on capital raising activity, fitting the category of Capital/Financing Update (CAP). The document length is about 6900 characters, which is consistent with a detailed financing announcement rather than a full report or a brief notice.
2021-03-22 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.